The Association between Concomitant Use of Serotonergic Antidepressants and Lithium-Induced Polyuria. A Multicenter Medical Chart Review Study

Abstract

Background: A previous study aimed at revealing the prevalence and determinants of lithium induced polyuria suggested an increased risk of polyuria (urine volume ≥3 L/24 h) in those using serotonergic antidepressants next to lithium.

Objective: The objective of our study was to re-evaluate this secondary finding in another study population.

Methods: We performed a multicenter medical chart review study in patients using lithium in whom a 24-hour urine volume had been determined.

Results: We included 116 patients, twelve (26%)of the 46 patients with polyuria used serotonergic antidepressants compared to ten (14%) of the 70 patients without polyuria. We found an increased risk of polyuria in lithium users concurrently using serotonergic antidepressants (oddsratio 2.86; 95% confidence interval 1.00–8.21), adjusted for age, gender, use of antiepileptics and thyreomimetics.

Conclusion: Our results confirm the previous secondary finding of an increased risk of polyuria in patients using serotonergic antidepressants next to lithium. Physicians should take this into account when evaluating polyuria in patients using lithium and when choosing an antidepressant in patients using lithium.

References

• 1 Adam P. Evaluation and management of diabetes insipidus.  Am Fam Physician. 1997;  55 2146-2153
• 2 Andersson KE. Changes in bladder tone during filling: pharmacological aspects.  Scand J Urol Nephrol Suppl. 1999;  201 67-72 , ; discussion 76-99
• 3 Asplund R, Johansson S, Henriksson S, Isacsson G. Nocturia, depression and antidepressant medication.  BJU Int. 2005;  95 820-823
• 4 Bendz H, Aurell M, Balldin J, Mathe AA, Sjodin I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium.  Nephrol Dial Transplant. 1994;  9 1250-1254
• 5 Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy.  Am J Kidney Dis. 1987;  10 329-345
• 6 Candura SM, Messori E, Franceschetti GP, D'Agostino G, Vicini D, Tagliani M. et al . Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists.  Br J Pharmacol. 1996;  118 1965-1970
• 7 Cavanaugh GL, Martin RE, Stenson MA, Robinson DD. Venlafaxine and urinary incontinence: possible association.  Ann Pharmacother. 1997;  31 372
• 8 Crammer JL. Drinking, thirst and water intoxication.  Br J Psychiatry. 1991;  159 83-89
• 9 Demling JH, Huang ML, Remmerie B, Mannaert E, Sperling W. Pharmacokinetics and safety of combination therapy with lithium and risperidone.  Pharmacopsychiatry. 2006;  39 230-231
• 10 Dunner DL. Optimizing lithium treatment.  J Clin Psychiatry. 2000;  61 ((Suppl 9)) 76-81
• 11 Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.  Am J Psychiatry. 2004;  161 217-222
• 12 Gitlin M. Lithium and the kidney: an updated review.  Drug Saf. 1999;  20 231-243
• 13 Gitlin MJ. Lithium-induced renal insufficiency.  J Clin Psychopharmacol. 1993;  13 276-279
• 14 Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women.  J Clin Psychiatry. 2004;  65 877-878
• 15 Hegde SS, Eglen RM. Peripheral 5-HT4 receptors.  Faseb J. 1996;  10 1398-1407
• 16 Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder.  CNS Drugs. 2006;  20 29-42
• 17 Maldonado G, Greenland S. Simulation study of confounder-selection strategies.  Am J Epidemiol. 1993;  138 923-936
• 18 MacCreadie RG, Morrison DP. The impact of lithium in South-west Scotland. I. Demographic and clinical findings.  Br J Psychiatry. 1985;  146 70-74
• 19 Movig KL, Baumgarten R, Leufkens HG, Laarhoven JH van, Egberts AC. Risk factors for the development of lithium-induced polyuria.  Br J Psychiatry. 2003;  182 319-323
• 20 Siegel AJ, Baldessarini RJ, Klepser MB, MacDonald JC. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management.  Harv Rev Psychiatry. 1998;  6 190-200
• 21 Siegler EL, Tamres D, Berlin JA, Allen-Taylor L, Strom BL. Risk factors for the development of hyponatremia in psychiatric inpatients.  Arch Intern Med. 1995;  155 953-957
• 22 Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs.  Drug Saf. 1995;  12 209-225
• 23 Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters.  Eur J Pharmacol. 1997;  340 249-258
• 24 Tonini M, Candura SM. 5-HT4 receptor agonists and bladder disorders.  Trends Pharmacol Sci. 1996;  17 314-316
• 25 Vestergaard P, Amdisen A, Schou M. Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment.  Acta Psychiatr Scand. 1980;  62 193-200
• 26 Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints.  Acta Psychiatr Scand. 1988;  78 434-441
• 27 Vieweg WV, David JJ, Rowe WT, Peach MJ, Veldhuis JD, Kaiser DL. et al . Psychogenic polydipsia and water intoxication–concepts that have failed.  Biol Psychiatry. 1985;  20 1308-1320
• 28 Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence.  Int Urogynecol J Pelvic Floor Dysfunct. 2000;  11 386-388
• 29 Yoshimura R, Ueda N, Shinkai K, Nakamura J. Two cases of bipolar disorder successfully stabilized for five years with a low dose of risperidone and lithium.  Pharmacopsychiatry. 2006;  39 233-234

Correspondence